



What is claimed is:

## 1. A compound of formula I



Wherein

 $R_1$  is selected from a) $R_2$  is lower alkyl or hydrogen $R_3$  is OH or hydrogen;


Z is O, C or -Z- is a bond between the two binding carbon atoms;

----- is a single or double bond between C2 and C3;

or salts thereof;

with the proviso that when  $R_1$  is a,  $R_3$  is hydrogen and that when  $R_1$  is b, Z is O or a bond, and  $R_2$  is methyl  $R_3$  is not OH.

## 2. A compound of formula I according to claim 1, wherein


 $R_1$  is ; $R_2$  is lower alkyl preferably methyl $R_3$  is hydrogen;

Z is O or -Z- is a bond between the two binding carbon atoms;

----- is a single bond;

or salts thereof.

3. A compound of formula I according to claim 1, wherein



R<sub>1</sub> is ;

R<sub>2</sub> is lower alkyl or hydrogen

R<sub>3</sub> is OH or hydrogen;

Z is O, C or -Z- is a bond between the two binding carbon atoms;

--- is a single or double bond;

or salts thereof;

with the proviso that when R<sub>2</sub> is methyl and Z is O or a bond R<sub>3</sub> is not OH.

4. A compound of formula I according to claim 1 selected from,

(Z)-(7R,8S,9S,16S)-8-Hydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-methyl-2-(2-methyl-thiazol-4-yl)-vinyl]-oxacyclohexadec-13-ene-2,6-dione;

(1S,3S,10R,11S,12S,16R)-11-Hydroxy-8,8,10,12,16-pentamethyl-3-[(E)-1-methyl-2-(2-methyl-thiazol-4-yl)-vinyl]-4,17-dioxa-bicyclo[14.1.0]heptadecane-5,9-dione;

16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-8-hydroxy-5,5,7,9-tetramethyl-oxacyclohexadec-13-ene-2,6-dione;

3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-11-hydroxy-8,8,10,12-tetramethyl-4,17-dioxa-bicyclo[14.1.0]heptadecane-5,9-dione;

(Z)-(7R,8S,9S,16S)-16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-8-hydroxy-5,5,7,9,13-pentamethyl-oxacyclohexadec-13-ene-2,6-dione;

(1S,3S,10R,11S,12S,16R)-3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-11-hydroxy-8,8,10,12,16-pentamethyl-4,17-dioxa-bicyclo[14.1.0]heptadecane-5,9-dione;

(E)-(7R,8S,9S,16S)-16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-8-hydroxy-5,5,7,9-tetramethyl-oxacyclohexadec-13-ene-2,6-dione;

(1S,3S,10R,11S,12S,16S)-3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-11-hydroxy-8,8,10,12-tetramethyl-4,17-dioxa-bicyclo[14.1.0]heptadecane-5,9-dione;

16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-4,8-dihydroxy-5,5,7,9-tetramethyl-oxacyclohexadec-13-ene-2,6-dione;  
3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;  
(E)-(4S,7R,8S,9S,16S)-16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-4,8-dihydroxy-5,5,7,9-tetramethyl-oxacyclohexadec-13-ene-2,6-dione;  
(1S,3S,7S,10R,11S,12S,16S)-3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-7,11-dihydroxy-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione;  
(3E,13E)-(7R,8S,9S,16S)-16-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-8-hydroxy-5,5,7,9-tetramethyl-oxacyclohexadeca-3,13-diene-2,6-dione;  
(E)-(1S,3S,10R,11S,12S,16S)-3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-11-hydroxy-8,8,10,12-tetramethyl-4,17-dioxabicyclo[14.1.0]heptadec-6-ene-5,9-dione;  
3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-7,11-dihydroxy-8,8,10,12-tetramethyl-4-oxabicyclo[14.1.0]heptadecane-5,9-dione; and  
(1S,3S,7S,10R,11S,12S,16R)-3-(1,2-Dimethyl-1H-benzoimidazol-5-yl)-7,11-dihydroxy-8,8,10,12-tetramethyl-4-oxabicyclo[14.1.0]heptadecane-5,9-dione

5. A pharmaceutical composition, comprising a compound of formula I, or a salt thereof, provided that salt-forming groups are present, according to one of claims 1 to 4, and one or more pharmaceutically acceptable carriers.


6. A compound of formula I according to one of claims 1 to 4, for use in a process for the diagnostic or therapeutic treatment of humans.

7. Use of a compound of formula I according to one of claims 1 to 4, for the preparation of a pharmaceutical product for the treatment of a tumour disease.

8. Use of a compound of formula I according to one of claims 1 to 4, as a pharmaceutical.

9. Process for the preparation of a compound of formula I according to claim 1, characterised in that a compound of formula I may be prepared by ring closure of a compound of formula III

- 61 -



followed by deprotection steps where necessary, wherein

R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> have the meaning defined in claim 1.